Clinical Efficacy and Safety Evaluation of Shiyiwei Huatan Tongluo Decoction(十一味化痰通络汤)in Syndrome Differentiation and Treatment of Ischemic Stroke of Wind-Phlegm Stagnation Syndrome
Objective To evaluate the clinical efficacy and safety of Shiyiwei Huatan Tongluo Decoction(十一味化痰通络汤)in the syndrome differentiation and treatment of ischemic stroke of wind-phlegm stagnation syndrome.Methods Eighty ischemic stroke patients in the Encephalopathy Department of Kaifeng Hospital of Traditional Chinese Medicine from July 2022 to May 2023 were selected,and the patients were assigned into western medicine(WM)group and traditional Chinese medicine(TCM)group using random number table method,each with 30 cases.WM group was given standardized western medicine treatment,while TCM group received standardized western medicine treatment plus Shiyiwei Huatan Tongluo Decoction.Then the National Institutes of Health Stroke Scale(NIHSS),modified Rankin scale(mRS),Barthel Index(BI),TCM syndrome scores and clinical efficacy rate were compared between two groups.Results At 7 d and 14 d of interventions,a decrease in NIHSS,mRS and TCM syndrome scores,along with an increase in BI were observed in both groups(all P＜0.05).TCM group scored lower on NIHSS,mRS and TCM syndrome,whereas higher on BI than those of WM group at 7 d and 14 d of interventions,with statistical difference(all P＜0.05).The clinical efficacy rate was 86.67％in TCM group,which was higher than 60.00％in WM group(P＜0.05).Conclusion Application of Shiyiwei Huatan Tongluo Decoction in the syndrome differentiation and treatment of ischemic stroke can effectively improve the clinical symptoms and neurological deficits in patients,and obtain good short-term efficacy.
万方数据
维普
